GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » Ending Cash Position

Advaxis (Advaxis) Ending Cash Position : $17.15 Mil (As of Mar. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Advaxis Ending Cash Position?

Advaxis's Ending Cash Position for the quarter that ended in Mar. 2023 was $17.15 Mil.

Advaxis's quarterly Ending Cash Position declined from Jul. 2022 ($28.15 Mil) to Oct. 2022 ($25.21 Mil) and declined from Oct. 2022 ($25.21 Mil) to Mar. 2023 ($17.15 Mil).

Advaxis's annual Ending Cash Position increased from Oct. 2020 ($25.18 Mil) to Oct. 2021 ($41.61 Mil) but then declined from Oct. 2021 ($41.61 Mil) to Oct. 2022 ($25.21 Mil).

Advaxis Ending Cash Position Historical Data

The historical data trend for Advaxis's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis Ending Cash Position Chart

Advaxis Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.12 32.36 25.18 41.61 25.21

Advaxis Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Mar23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.73 32.09 28.15 25.21 17.15

Advaxis Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Advaxis's Ending Cash Position for the fiscal year that ended in Oct. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=41.614+-16.406
=25.21

Advaxis's Ending Cash Position for the quarter that ended in Mar. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.724+14.424
=17.15

Advaxis Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Advaxis's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Advaxis (Advaxis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » Ending Cash Position
Comparable Companies
ARTH BVXV BLCM CYCC ENVB BLPH SNGX APTX ZVSA APVO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 SGEN XBRU:ARGX BNTX HKSE:02269
Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540
Website
https://www.advaxis.com
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Executives
Roy Golan officer: Chief Financial Officer 24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly director C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach director C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg director 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib director C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel 10 percent owner YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070